Publications by authors named "H Cajigas"
Objective: To determine the prevalence of portopulmonary hypertension in patients referred for liver transplant evaluation.
Methods: Medical records were reviewed for 986 consecutive patients referred for liver transplant evaluation who were screened for pulmonary hypertension with echocardiography from February 1, 2021, to January 31, 2022, across 3 liver transplant centers.
Results: Of 934 patients eligible for analysis, mean (SD) age was 57 (11) years, 558 (59.
Article Synopsis
- Pulmonary embolism (PE) is a significant health issue, being the third leading cause of illness and death globally, with submassive PE making up 40% of this burden.
- A study reviewed 22 patients with submassive PE who underwent mechanical thrombectomy (MT), showing a successful thrombus removal rate of 82% and no major bleeding complications.
- Results indicated that MT led to shorter hospital stays and lower in-hospital mortality rates compared to standard anticoagulation therapy alone, despite the small sample size.
Background: Patients with COPD frequently demonstrate pulmonary hypertension (PH). Severe PH in patients with COPD, identified by pulmonary vascular resistance (PVR) of > 5 Wood units (WU), is closely linked to impaired transplant-free survival. The impact of PH-targeting pharmacotherapy in this context remains unclear.
View Article and Find Full Text PDFArticle Synopsis
- - Pulmonary hypertension (PH) is a serious and varied disease, necessitating accurate assessments for effective treatment, and its existing risk models require further investigation, especially outside of group 1 (PAH).
- - This study analyzed 8,565 patients with different types of PH (groups 1 to 4) to determine if risk scores developed for pulmonary arterial hypertension (PAH) could predict outcomes in all groups.
- - Results showed that all risk scores were effective in predicting patient outcomes across PH groups, with the REVEAL scores proving to be the most statistically powerful and detailed.
Chronic lung disease (CLD) is the second leading cause of pulmonary hypertension (PH) and is associated with significant morbidity and mortality. Although PH associated with CLD (PH-CLD) leads to impaired health-related quality of life (HRQOL), there are no validated tools to assess HRQOL in PH-CLD. The Pulmonary Arterial Hypertension-Symptoms and Impact Questionnaire (PAH-SYMPACT) is an HRQOL instrument aimed at assessing the symptoms and impact of PH on overall function and well-being.
View Article and Find Full Text PDF